左龙右鲤2018-03-19 09:03
$Sorrento Therapeutics, Inc. (SRNE)$ 这个年报我很满意,体现了2017年的三个成果:
1)收入大幅增长,主要是与 $新基制药(CELG)$ 合资Celularity,索伦托持股25%。同时索伦托将CD38的一个CAR专利技术授权给了Celularity,这个合作导致royalties and licenses增加了1.4亿美元Celularity可不是...查看全文
药渡2018-03-11 20:19
经过17年一年的平静,生物医药领域再次迎来了一波并购热潮。2018年的前两个月就已经完成了多笔重磅交易。新基公司(Celgene)计划以70亿美元和90亿美元的价格收购ImpactBiomedicines公司和朱诺医药(Juno Therapeutics)。赛诺菲公司(Sanofi)关注罕见血液病治疗领域,分别以116亿美金和48亿美金的价格...查看全文
岁月静好-吉星高照2018-03-06 15:45
2017-2022年全球医药市场分析和展望网页链接
从治疗领域Therapy Area来看,以下十个领域市场规模最大。
(1)肿瘤Oncology仍然是最大的细分市场,2016-2022年CAGR为12.7%,2022年将达到1922亿美金销售,占全球市场份额的17.5%。
(2)糖...查看全文
长鲸骑士2018-03-03 20:09
$新基制药(CELG)$ 这是要换CEO的节奏?
Heard on the Street: Celgene's Missteps Becoming Too Frequent for Investors -- WSJ
This article is being republished as part of our daily reproduction of WSJ.com articles that also appeared in the U.S. print edition of The Wa...查看全文
kellyqiao2018-03-01 10:44
之前分享过2017-2022年的全球医疗器械市场,2017-2022年全球医疗器械市场规模及机会展望,本篇看下Evaluate对基于全球6500家药物公司的研究而做出的2017-2022年全球药物市场的分析和展望。
一.市场规模和增长速度
2017年全球处方药市场规模为7740亿美金,预计2017-2022年CAGR年增长速度 ...查看全文
$新基制药(CELG)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001104659-20-013792 Size: 69 KB 网页链接
$新基制药(CELG)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001104659-20-013796 Size: 42 KB 网页链接
$新基制药(CELG)$ 15-12B Securities registration termination [Section 12(b)] Accession Number: 0001140361-19-022527 Act: 34 Size: 15 KB 网页链接
$新基制药(CELG)$ S-4 POS Securities issued, formation of bank or savings and loan holding company [General Instruction G], post-effective amendments Accession Number: 0001140361-19-022225 Act: 33 Size: 20 KB 网页链接
$新基制药(CELG)$ S-4 POS Securities issued, formation of bank or savings and loan holding company [General Instruction G], post-effective amendments Accession Number: 0001140361-19-022228 Act: 33 Size: 20 KB 网页链接
$新基制药(CELG)$ S-4 POS Securities issued, formation of bank or savings and loan holding company [General Instruction G], post-effective amendments Accession Number: 0001140361-19-022200 Act: 33 Size: 20 KB 网页链接
$新基制药(CELG)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001140361-19-022201 Act: 33 Size: 39 KB 网页链接
$新基制药(CELG)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001140361-19-022206 Act: 33 Size: 39 KB 网页链接
$新基制药(CELG)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001140361-19-022210 Act: 33 Size: 39 KB 网页链接
$新基制药(CELG)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001140361-19-022217 Act: 33 Size: 39 KB 网页链接